Innoviva - 15 Year Stock Price History | INVA
Historical daily share price chart and data for Innoviva since 2011 adjusted for splits and dividends. The latest closing stock price for Innoviva as of June 12, 2026 is 22.74.
- The all-time high Innoviva stock closing price was 31.90 on July 11, 2013.
- The Innoviva 52-week high stock price is 25.14, which is 10.6% above the current share price.
- The Innoviva 52-week low stock price is 16.52, which is 27.4% below the current share price.
- The average Innoviva stock price for the last 52 weeks is 20.74.
| Innoviva Historical Annual Stock Price Data | ||||||
|---|---|---|---|---|---|---|
| Year | Average Stock Price | Year Open | Year High | Year Low | Year Close | Annual % Change |
| 2026 | 22.1460 | 19.8700 | 24.2400 | 19.3100 | 22.7400 | 13.76% |
| 2025 | 19.0618 | 17.4000 | 22.2800 | 16.6700 | 19.9900 | 15.22% |
| 2024 | 17.2377 | 16.3700 | 20.3200 | 14.4000 | 17.3500 | 8.17% |
| 2023 | 12.9066 | 13.2700 | 16.2700 | 10.7300 | 16.0400 | 21.06% |
| 2022 | 15.2545 | 17.4500 | 20.2500 | 11.6100 | 13.2500 | -23.19% |
| 2021 | 14.1809 | 12.4800 | 18.7200 | 11.0600 | 17.2500 | 39.23% |
| 2020 | 12.5718 | 13.9300 | 15.2600 | 8.1100 | 12.3900 | -12.50% |
| 2019 | 13.6160 | 17.3000 | 20.0600 | 10.0500 | 14.1600 | -18.85% |
| 2018 | 15.2612 | 14.4300 | 18.2600 | 13.4400 | 17.4500 | 22.97% |
| 2017 | 12.7226 | 11.1400 | 14.7500 | 10.4300 | 14.1900 | 32.62% |
| 2016 | 11.2488 | 10.3200 | 13.7700 | 8.2300 | 10.7000 | 1.52% |
| 2015 | 13.4310 | 13.2571 | 19.5225 | 6.7800 | 10.5400 | -22.07% |
| 2014 | 21.1900 | 27.1549 | 30.2893 | 12.1381 | 13.5248 | -49.29% |
| 2013 | 24.5437 | 16.7867 | 31.8977 | 15.0811 | 26.6687 | 60.30% |
| 2012 | 16.7085 | 15.3354 | 23.7064 | 12.2609 | 16.6370 | 0.63% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $1.760B | $0.411B |
| Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Pfizer (PFE) | United States | $153.074B | 8.33 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |